Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredient

• US 9,296,751 B1
• Filed: 10/15/2015
• Issued: 03/29/2016
• Est. Priority Date: 10/16/2014
• Status: Active Grant

• Current Assignee: Industry Academic Cooperation Foundation
• Original Assignee: Industry Academic Cooperation Foundation
• Inventors: Kim, Ikyon, Namkung, Wan, Sung, Jonghyuk
• Primary Examiner(s): Aulakh, Charanjit
• Application Number:
  US14/884,179
• Publication Number:
  US 20160108042A1
• Time in Patent Office: 166 Days
• Field of Search: 514/285, 546/70
• US Class Current: 1/1
• CPC Class Codes: C07D 471/14 Ortho-condensed systems

Abstract

Provided are an indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof, and a method for preparing the same. The indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof may function as an agonist of cystic fibrosis conductance transmembrane regulator, and thus may be useful for an agent for preventing or treating diseases caused by degradation of activity of cystic fibrosis conductance transmembrane regulator and for a pharmaceutical composition for stimulating proliferation of stem cells.

Claims

1. An indolizino[3,2-c]quinoline derivative represented by the following Chemical Formula 1 or pharmaceutically acceptable salt thereof:

2. The indolizino[3,2-c]quinoline derivative represented by Chemical Formula 1 or pharmaceutically acceptable salt thereof according to claim 1, wherein the aryl is selected from phenyl, naphthyl, anthryl and biaryl.

3. The indolizino[3,2-c]quinoline derivative represented by Chemical Formula 1 or pharmaceutically acceptable salt thereof according to claim 1, wherein the heteroaryl is selected from pyridyl, pyrimidyl, thiophenyl, pyrollyl and furanyl.

4. The indolizino[3,2-c]quinoline derivative represented by Chemical Formula 1 or pharmaceutically acceptable salt thereof according to claim 1, wherein the C1-C6 alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-propyl, isopropyl, n-hexyl and isohexyl.

5. The indolizino[3,2-c]quinoline derivative represented by Chemical Formula 1 or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound represented by Chemical Formula 1 is at least one selected from the group consisting of the following Chemical Formula 6 through Chemical Formula 49:

6. A method for preparing an indolizino[3,2-c]quinoline derivative represented by the following Chemical Formula 1 by reacting a compound represented by the following Chemical Formula 2 with an aldehyde in the presence of a catalyst:

7. The method for preparing an indolizino[3,2-c]quinoline derivative according to claim 6, wherein the catalyst is any one selected from FeCl₃, AlCl₃, BiCl₃, InCl₃, PTSA (p-toluenesulfonic acid) and PPTS (pyridinium p-toluenesulfonic acid).

8. The method for preparing an indolizino[3,2-c]quinoline derivative according to claim 6, wherein the reaction is carried out in a solvent selected from methylene chloride, N,N-dimethytformamide and tetrahydrofuran at 20-80°

C.

9. The method for preparing an indolizino[3,2-c]quinoline derivative according to claim 6, wherein the compound represented by the above Chemical Formula 2 is obtained by reducing a compound represented by the following Chemical Formula 3:

10. The method for preparing an indolizino[3,2-c]quinoline derivative according to claim 9, wherein the compound represented by the above Chemical Formula 3 is obtained by reacting a compound represented by the following Chemical Formula 4 with a compound represented by the following Chemical Formula 5:

11. An agonist of cystic fibrosis conductance transmembrane regulator (CFTR), comprising the indolizino[3,2-c]quinoline derivative represented by the following Chemical Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient:

12. A pharmaceutical composition for treating diseases caused by degradation of activity of cystic fibrosis conductance transmembrane regulator, comprising the indolizino[3,2-c]quinoline derivative represented by the following Chemical Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient:

13. The pharmaceutical composition for treating diseases caused by degradation of activity of cystic fibrosis conductance transmembrane regulator according to claim 12, wherein the disease caused by degradation of activity of cystic fibrosis conductance transmembrane regulator is at least one selected from cystic fibrosis and dry eye syndrome.

14. A pharmaceutical composition for stimulating stem cell proliferation, comprising the indolizino[3,2-c]quinoline derivative represented by the following Chemical Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient:

15. The pharmaceutical composition for stimulating stem cell proliferation according to claim 14, wherein the stem cell is any one selected from adipose-derived stem cells, neural stem cells, mesenchymal stem cells and adult stem cells.